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ABSTRACT
Minor histocompatibility antigens (mHags) HA-1 and HA-2 are encoded by biallelic loci, with immunogenic
variants, HA-1H and HA-2V, which induce strong HLA-A2–restricted alloreactive T-cell responses, and
nonimmunogenic counterparts, HA-1R and HA-2M, which represent functional null alleles that are poorly
presented by HLA class I molecules. HA-1 and HA-2 are potential targets of selective graft-versus-leukemia
and graft-versus-tumor reactivity after allogeneic hematopoietic stem cell transplantation (HSCT); however,
these applications are restricted to a limited number of patients. Here, we show that a far more frequent
application of HA-1 and HA-2 disparity relies on their use as markers for the state of host chimerism after
allogeneic HSCT. We have determined allelic frequencies of 29.3% and 70.7% for HA-1H and HA-1R,
respectively, and of 83.7% and 16.3% for HA-2V and HA-2M, respectively, in >200 healthy individuals from
northern Italy. Similar frequencies were observed in nearly 100 patients affected by hematologic malignancies
or solid tumors, thus showing that HA-1 and HA-2 variability are not associated with the presence of cancer.
On the basis of these data, we predict that HA-1 and HA-2 can be used in 32.8% and 23.5% of Italian transplant
patients, respectively, as markers for the state of host chimerism, whereas exploitation of disparity for these
mHags for targeted immunotherapy will be possible in 10.7% and 1.1% of Italian patients, respectively.
Retrospective HA-2 typing of bone marrow aspirates obtained from a patient during complete remission or
recurrence of acute myeloid leukemia after haploidentical HSCT showed the feasibility of using HA-2 as a
surrogate marker for disease monitoring. Because of an apparent north-south gradient for HA-1 allelic
frequencies, with higher frequencies for the HA-1H variant reported in white populations from Southern
Europe as compared with Northern Europe and North America, the diagnostic applicability of HA-1 disparity
will be slightly more frequent in transplant patients from the north. Taken together, our data show that
determination of HA-1 and HA-2 variability can be an important parameter for the selection of allogeneic stem
cell donors, in particular for patients affected by hematologic malignancies without a tumor-specific molecular
marker.
© 2006 American Society for Blood and Marrow Transplantation
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9NTRODUCTION
Minor histocompatibility antigens (mHags) are
eptides derived from largely undeﬁned polymorphic
roteins encoded throughout the human genome and
resented by self major histocompatibility complex
olecules to alloreactive T cells [1]. The mHags play
n important role in allogeneic hematopoietic stem
ell transplantation (HSCT) because they are the only
argets of graft-versus-host disease in HLA-matched
ibling or unrelated donor transplantation, and they
ontribute to this major clinical complication also af-
er partially HLA-mismatched HSCT [2,3]. Con-
ersely, mHags are also responsible for the immuno-
herapeutic effect mediated by donor T cells after
llogeneic HSCT, both against leukemia (graft versus
eukemia; GVL) and against solid tumors (graft versus
umor; GVT) [3-6]. Considerable effort has been
pent on trying to separate graft-versus-host disease
rom GVL/GVT. One approach to tackle this chal-
enge relies on the identiﬁcation of mHags selectively
xpressed in tissues of hematopoietic origin but absent
n other cell types. Particular interest has been raised
y 2 mHags that fulﬁll these criteria, HA-1 and HA-2:
oth are encoded by biallelic gene systems with one
mmunogenic and a second nonimmunogenic variant
7,8]. In particular, the immunogenic peptides en-
oded by HA-1H and HA-2V are presented on the cell
urface by HLA-A2 molecules and recognized by
LA-A2–restricted cytotoxic T cells, whereas the
onimmunogenic variants HA-1R and HA-2M are func-
ionally silent because of poor presentation by HLA class
molecules. HA-1, which is expressed not only on he-
atopoietic cells, but also in a variety of solid tumors
and, hence, is a potential target of GVT [9]), encodes a
rotein of unknown function [10,11]. The protein en-
oded by HA-2 belongs to the family of myosins in-
olved in formation of the cell cytoskeleton [12].
HA-1 and HA-2 are potential targets of immuno-
herapy in patients who carry HLA-A2 and at least 1
mmunogenic mHag variant after transplantation
rom a donor homozygous for the nonimmunogenic
ariant [13-18]. In such patients, tracing of HA-1–
peciﬁc cytotoxic T lymphocytes by tetramer staining
as been successfully used to monitor GVL activity
fter transplantation [14]. However, this important
pplication is limited to a restricted number of pa-
ients because of the allelic frequencies of HA-1 and
A-2 variants [19]. Recently, HA-1 has been used as
arker for maternal-fetal microchimerism in individ-
als sensitized to HA-1 by pregnancy or multiple
lood transfusions [20]. We show here that a far more
requent application of HA-1 and HA-2 disparity after
llogeneic HSCT relies on the use of these 2 mHags
s molecular markers for the state of host chimerism
HC). By systematic comparison of HA-1 and HA-2
llelic frequencies in Italy with those previously re- 0
6orted for other populations [10,11,19,21-25], we
emonstrate the presence of a north-south gradient
or the frequencies of HA-1 variants. This gradient
etermines a slightly higher diagnostic applicability of
A-1 disparity for patients from Northern Europe
nd North America as compared with Mediterranean
ountries.
ATERIALS AND METHODS
tudy Population
A total of 208 and 199 healthy blood donors from
orthern Italy were typed for HA-1 and HA-2 poly-
orphisms, respectively. A total of 99 Italian patients
ho underwent allogeneic HSCT from HLA-identi-
al (n  59) or haploidentical (n  33) family donors
r from HLA-identical unrelated donors (n  7) for
ematologic malignancies (n  82) or solid tumors
n  17) were also included in the study. All 99
atients were typed for HA-1 variants, and HA-2
yping was performed on 91 of these patients, 74 of
hom had hematologic malignancies. One patient,
atient 20, was heterozygous for the 2 HA-2 variants
nd received a transplant from an HA-2V homozygous
aploidentical family donor for acute myeloid leuke-
ia. This patient experienced initial complete disease
emission (CR) after transplantation (CR1) but expe-
ienced disease relapse at day150 after transplantation
s evidenced by morphologic analysis (23% leukemic
lasts). Bone marrow aspirates from this patient at day
90 (CR1) and 150 (relapse) were retrospectively
yped for HA-2 by using the sequence-speciﬁc polymer-
se chain reaction (PCR) ampliﬁcation, as described be-
ow.
enomic Typing of HA-1 and
A-2 Polymorphisms
Genomic DNA was extracted from 210 L of
eripheral ethylenediaminetetraacetic acid-blood by
sing a commercial DNA-extraction kit (Sigma, St.
ouis, MO). HA-1 and HA-2 typing by PCR-based
equence-speciﬁc priming was performed according
o previously published protocols [10,26], with slight
odiﬁcations. These modiﬁcations consisted of the
se of only 1 primer mix for each variant and the
nclusion of primers for ampliﬁcation of HLA-DRB
27] or HLA-DPB1 [27] as an internal control for
ach reaction (Table 1). PCR conditions were identi-
al for the ampliﬁcation of HA-1 and HA-2; thermal
ycler programs were used as described previously
10,26]. PCR reactions were performed in 25 L of
reaction mixture that contained 5 pmol of each
A-1–speciﬁc or HA-2–speciﬁc primer, 2.5 pmol of
nternal control primer, 80 ng of genomic DNA, 5
-Buffer (Invitrogen, NV Leek, The Netherlands),
.25 mmol/L deoxynucleoside triphosphates (Invitro-
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Ben), 2 mmol/L MgCl2 (Applied Biosystems, Foster
ity, CA), and 0.6 U of AmpliTaq DNA polymerase
Applied Biosystems). Amplicons were separated by
% agarose gel electrophoresis and yielded speciﬁc
ands of 190 and 274 base pairs (bp) for HA-1 and
A-2, respectively. Internal control bands had a size
f 276 bp for HLA-DRB and of 327 bp for HLA-
PB1. An HA-2–typed B-lymphoblastoid cell line,
enerously provided by Els Goulmy, Leiden, The
etherlands, was used as a reference for the homozy-
osity of HA-2M.
alculation of the Probability of Using HA-1 or
A-2 Disparity for Targeted Immunotherapy after
llogeneic HSCT
The probability of being able to exploit HA-1 or
A-2 disparity for GVL activity after allogeneic
SCT was calculated on the basis of allelic frequen-
ies for the immunogenic and the nonimmunogenic
ariants of these 2 mHags and of the reported pheno-
ypic frequencies for HLA-A2 [28] in different popu-
ations. The prediction was based on the concept that
or targeted immunotherapy, the patient (and, in
LA-identical HSCT, consequently also the donor)
ust express the HLA-A2 restriction element and at
east 1 allele that encodes the immunogenic variants
A-1H or HA-2V. In contrast, the donor must be
omozygous for the nonimmunogenic alleles because
he presence of the immunogenic variants leads to
lonal deletion of self-reactive mHag-speciﬁc T cells
29]. On the basis of these considerations, the percent-
ge P-GVL of patients in whom a GVL effect against
he immunogenic HA-1H and HA-2V variants could
e exploited was calculated according to the formula
able 1. Primer Pairs Used in This Study for HA-1 and HA-2
enomic Typing
Primer Nucleotide Sequence (5=-3=) Position
A1Cfor* GTGCTGCCTCCTGGACACTG Exon A
A1Hrev* TGGCTCTCACCGTCATGCAG Exon A/
intron
A1Rrev* TGGCTCTCACCGTCACGCAA Exon A/
intron
A2Cfor† ACAGTCTCTGAGTGGCTCAGC Intron
A2Vrev† CAGCTCCTGGTAGGGGTTCAC Exon
A2Mrev† CAGCTCCTGGTAGGGGTTCAT Exon
RBfor‡ CGTGTCCCCACAGCACGTT Exon 2
RBrev‡ CCGCTGCACTGTGAAGCT Exon 2
PBAmpA§ GAGAGTGGCGCCTCCGCTCAT Intron 1
PBAmpB§ GCCGGCCCAAAGCCCTCACTC Intron 2
Primer sequence was reported previously [10].
Primer sequence was reported previously [26].
Primer for ampliﬁcation of HLA-DRB as an internal control for
HA-1 typing [27].
Primer for ampliﬁcation of HLA-DPB1 as an internal control for
HA-2 typing [27].p-GvL pNI pII pNN pA2 100, †
B&MThere pNI indicates the frequency of heterozygosity
or the nonimmunogenic (N) and the immunogenic
I) mHag variant; pII indicates the frequency of ho-
ozygosity for the immunogenic (I) mHag variant;
NN indicates the frequency of homozygosity for the
onimmunogenic (N) mHag variant, and pA2 indi-
ates the phenotypic frequency for HLA-A2 [28].
alculation of the Probability of Using HA-1 or
A-2 Disparity as a Marker for the State of HC
fter Allogeneic HSCT
This application requires the presence in the pa-
ient of an HA-1 or HA-2 variant not shared by the
onor and is independent from the expression of
LA-A2 and from the presence or absence of an
mmunogenic mHag variant. The percentage P-HC
f patients predicted in whom this diagnostic applica-
ion could be exploited was calculated according to the
ormula
-HC pII pNI pNN pNN
 pNI pII 100,
here the variables are as described previously.
ESULTS
llelic Frequencies of HA-1 in the
talian Population
Genomic typing of HA-1 was applied to 208
ealthy blood donors from northern Italy. The allelic
requency of HA-1H and HA-1R was 29.3% and
0.7%, respectively (Table 2). To determine whether
A-1 variability is associated with the presence of
ancer, 99 Italian patients affected by hematologic
alignancies (n  82) or solid tumors (n  17) were
lso typed for HA-1. The resulting allelic frequencies
ere very similar to those observed in healthy indi-
iduals (Table 2), thus suggesting that HA-1 variants
able 2. Allelic Frequencies of HA-1 and HA-2 in Healthy
ndividuals or Cancer Patients from Italy
Variable
Allelic Frequency (%)
Healthy Individuals* Cancer Patients†
A-1H 29.3 32.8
A-1R 70.7 67.2
A-2V 83.7 81.7
A-2M 16.3 18.3
A-1 and HA-2 polymorphisms were characterized by genomic
PCR sequence-speciﬁc priming as described in “Materials and
Methods.” In case only 1 allele was detected, homozygosity was
assumed, and the allele was counted twice for calculation of
allelic frequencies.
n  208 for HA-1; n  199 for HA-2.
n  99 for HA-1; n  91 for HA-2.
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9re not involved in the predisposition to or protection
rom the development of cancer.
North-South Frequency Gradient for HA-1
llelic Variants
The allelic frequencies observed for HA-1 variants
n this study were compared with those reported by
thers in healthy white individuals from Southern or
orthern Europe and North America [10,11,19,21-
5] (Table 3). It is interesting to note that the fre-
uency of HA-1H was generally higher in populations
rom the north (mean  SD, 46.4%  8.7%) as
ompared with the south (30.6  1.9%), whereas the
nverse correlation was evident for HA-1R (mean 
D, 53.6%  8.7% and 69.4%  1.9% in northern
nd southern countries, respectively; Table 3).
llelic Frequencies of HA-2 in the
talian Population
In 199 healthy blood donors typed for HA-2 poly-
orphism, allelic frequencies of 83.7% and 16.3%
ere observed for HA-2V and HA-2M, respectively
Table 2). A total of 91 cancer patients studied for
A-1 polymorphism were also typed for HA-2.
gain, no skewing of the polymorphism was associ-
ted with the presence of a malignant disorder (Table 2).
his ﬁnding argues against an involvement of HA-2
ariants in the pathogenesis of cancer—a possibility
heoretically compatible with the role of this protein
n formation of the cytoskeleton [12]. The data ob-
ained here for the Italian population are in line with
hose previously reported for the Dutch, in which the
llelic frequency of HA-2V and HA-2M was 77.6% and
2.4%, respectively [23,26].
linical Applications of HA-1 and
A-2 Polymorphisms
On the basis of our data, we calculated that the prob-
able 3. Allelic Frequencies of HA-1 in Different White Populations
Variable
Al
Southern Europe
Italy*
(n  210)
Spain†
(n  203)
Greece‡
(n  98) Mean§
Dut
(n 
A-1H 29.3 32.8 29.6 30.6  1.9 44
A-1R 70.7 67.2 70.4 69.4  1.9 55
This study.
Reported in reference [24].
Reported in reference [22].
Mean  SD.
Reported in references [10] and [23].
Reported in reference [21].
Reported in reference [25].
*Reported in reference [19].
†North American whites, reported in reference [11].bility for a given Italian patient of carrying HLA-A2
842.8% [28]) and of being mismatched in the GVL
irection with his/her allogeneic HSC donor would be
0.7% for HA-1 and 1.1% for HA-2 (Table 4). These
redicted percentages were in line with those actually
bserved in the series of patients who underwent al-
ogeneic HSCT at our center and who presented the
ossibility of exploiting GVL targeted against HA-1
r HA-2 in 15.1% (15/99) and 1% (1/91) of the cases,
espectively (Table 4). It is important to note that the
ossibility of using patient-speciﬁc HA-1 or HA-2
lleles as markers for the state of HC after transplan-
ation can be predicted to be present in 32.8% and
3.5% of Italian transplantation patients, respectively
equency (%)
Northern Europe and North America
Germany¶
(n  201)
Germany#
(n  65)
Germany**
(n  545)
United
States††
(n  160) Mean§
39.0 45.2 61.3 42.0 46.4  8.7
61.0 54.8 38.7 58.0 53.6  8.7
able 4. Clinical Applications of HA-1 and HA-2 Polymorphisms in
llogeneic HSCT
Variable
% Application for HA-1
Polymorphism
% Application for HA-2
Polymorphism
Predicted Observed* Predicted Observed†
VL‡ 10.7 15.1 1.1 1
C§ 32.8 25.6 23.5 16.2
he values in the column “Predicted” were calculated on the basis
of allelic frequencies of HA-1 and HA-2 variants in the Italian
population, reported in Table 2. The values in the column
“Observed” refer to the actual number of pairs with the relevant
clinical application in our series.
Observed: n  99 for GVL; n  82 for HC (only patients with
hematologic malignancies were considered for HC).
Observed: n  91 for GVL; n  74 for HC (only patients with
hematologic malignancies were considered for HC).
GVL: potential for graft-versus-leukemia (GVL) reactivity in HLA-
identical donor recipient pairs expressing HLA-A2, present with a
phenotypic frequency of 42.8% for HLA-A2 in Italy [28]. Calcu-
lations were based on the formula speciﬁed in “Materials and
Methods.”
HC: possibility of HC detection by tracing of HA-1 or HA-2
variants as markers for reappearance of cells of host origin after
allogeneic HSCT. Calculations were based on the formula spec-lelic Fr
ch
100)
.3
.7iﬁed in “Materials and Methods.”
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BTable 4). This prediction reﬂected the actual situa-
ion in our series of patients who received transplants
or hematologic malignancies, in whom this applica-
ion was possible in 25.6% (21/82) and 16.2% (12/74)
or HA-1 and HA-2, respectively. A total of 89%
73/82) and 89.1% (66/74) of these patients lacked a
umor-speciﬁc molecular marker. In 28.7% (21/73)
nd 15.1% (10/66) of patients without a tumor-spe-
iﬁc marker, HA-1 and HA-2, respectively, could be
sed as surrogates for the reappearance of host cells,
ncluding leukemic blasts. Overall, in the 66 patients
ithout a molecular tumor marker who were typed for
A-1 and HA-2, a patient-speciﬁc allele of 1 or both
f these mHags could be used as a surrogate marker
or disease recurrence in 36.3% (24/66) of cases (data
ot shown). One of these patients, patient 20, who
eceived a transplant from an HA-2–disparate hap-
oidentical family donor for acute myeloid leukemia,
xperienced an initial CR followed by disease relapse.
A-2 typing was retrospectively used for disease
onitoring in bone marrow aspirates after HSCT
Figure 1). Disease recurrence could be evidenced by
racing the patient-speciﬁc HA-2M allele at the time of
elapse.
The similarity of HA-1 allelic frequencies (Table 3)
nd of HLA-A2 expression [28] in Italy and in other
opulations from Southern Europe, such as Spain and
reece, suggests that the predictions made for Italy
ill also apply to other Mediterranean countries. In
ontrast, in populations from Northern Europe, such
s the Dutch and Germans, as well as in North Amer-
can whites, the frequency of HA-1H is higher than in
he south (Table 3). In addition, in these populations,
igure 1. Monitoring of disease recurrence by tracing the patient-
peciﬁc HA-2M allele in patient 20. Genomic HA-2 typing of patient
0 and her haploidentical family stem cell donor was performed as
escribed in “Materials and Methods.” PCR fragments of 327 and 274
p correspond to the internal control gene and the HA-2 allele,
espectively.M andV stand for the polymorphism HA-2M and HA-2V,
espectively. Agarose gel electrophoresis is shown of PCR products
btained from peripheral blood of the donor (lane 1), of the patient
efore transplantation (lane 2), and of bone marrow aspirates from the
atient drawn in complete clinical remission at day 90 (lane 3) or in
elapse at day150 (lane 4) after HSCT. —, PCR mix ampliﬁed in the
bsence of template DNA. The molecular weight marker used isoeneRuler 50bp DNA ladder (MBI Fermentas, Hanover, MD).
B&MTLA-A2 is slightly more frequent than in the south
Germany, 47.8%; North American whites, 48.6%;
ean, 48.2% [27]). On the basis of these data, it can
e predicted that HA-1 can be exploited for therapeu-
ic (GVL) or diagnostic (HC) purposes in approxi-
ately 9.9% and 37.4%, respectively, of patients from
he north (data not shown).
ISCUSSION
The mHags HA-1 and HA-2 have raised consid-
rable interest as targets for selective immunotherapy
fter allogeneic HSCT because they are among the
ew mHags characterized at the molecular level that
re expressed on hematopoietic tissues and some solid
umors, but not on healthy tissues of different origin.
he potential applicability of this approach is, how-
ver, hampered by the allelic distribution of HA-1
nd, more so, of HA-2, which restricts the percentage
f patients predicted to beneﬁt from GVL mediated
y these 2 mHags to approximately 10% and 1% for
A-1 and HA-2, respectively. Despite the north-
outh frequency gradient demonstrated here for HA-1
llelic variants, these numbers do not vary substan-
ially between patients from northern and southern
ountries because the higher frequency of the immu-
ogenic HA-1H allele in northern populations is com-
ensated for by a higher frequency of HLA-A2 in
hese populations [28]. For HA-2, no apparent differ-
nces in allelic distribution were found in Italy as
ompared with The Netherlands [23], the only pop-
lation analyzed for HA-2 variability so far. More
opulations need to be studied to conﬁrm the appar-
nt absence of frequency differences for HA-2 variants
n northern and southern countries.
This study is the ﬁrst to systematically compare
llelic HA-1 and HA-2 frequencies in different popu-
ations and to calculate the possibility of exploiting the
isparity for these mHags for clinical or diagnostic
urposes in patients undergoing allogeneic HSCT. It
s interesting to note that we show here that the
otential applications of HA-1 and HA-2 disparity for
iagnostic purposes, in terms of determination of HC
tatus after transplantation, are far greater than those
or therapeutic purposes in terms of GVL activity.
his is because exploitation of mHag disparity for
iagnostic purposes is independent from the presence
f HLA-A2 and from the presence or absence of an
mmunogenic or nonimmunogenic variant in the pa-
ient or in the donor. In this setting, patient-speciﬁc
A-1 or HA-2 alleles can be detected by PCR-based
equence-speciﬁc priming typing in the peripheral
lood or bone marrow of patients who have received
ransplants. It is likely that the sensitivity of this
ethod would be improved by using nested PCR, as
pposed to single-step PCR. Indeed, nested PCR am-
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1liﬁcation of HA-1 variants has recently been demon-
trated to detect HA-1 alleles expressed by as few as 1
n 105 cells [20].
We have demonstrated that tracing a patient-spe-
iﬁc HA-2 variant could be used for detection of
isease recurrence after allogeneic HSCT. It should
e noted that the reappearance of cells carrying host-
peciﬁc HA-1 or HA-2 alleles in their genome is most
requently indicative of disease relapse, but it can also be
ue to graft rejection or autologous marrow reconstitu-
ion, especially if nonmyeloablative transplantation con-
itioning regimens are used. These possibilities can in
ome cases be discriminated by performing the analysis
n subpopulations of cells expressing deﬁned surface
xpression markers after ﬂuorescence-activated cell sort-
ng. For instance, T lymphocyte–mediated acute graft
ejection is associated with a predominance of host cells
n the lymphoid CD3 compartment, whereas relapsing
eukemia will be predominantly present in the subpopu-
ation of cells sorted for markers of the initial leukemic
henotype. For correct interpretation of mixed HC
ased on the reappearance of host-speciﬁc mHags, cli-
icians also need to consider the transplantation regi-
en, the presence or absence of T-cell depletion, and
he individual relapse risk of the patient on the basis of
he underlying disease. Another parameter to be taken
nto account is the time elapsed after transplantation,
ecause mixed HC is indicative of graft rejection in the
arly phase, whereas it is more frequently associated with
elapse in the later phase after transplantation. On the
asis of these considerations, it is evident that the reap-
earance of host mHags can be used to detect different
nitiating adverse clinical events, including relapse, but
annot by default be interpreted as indication for the
resence of minimal residual disease (MRD).
Conversely, new molecular markers suitable for
ensitive detection of MRD after allogeneic HSCT
or hematologic malignancies are urgently needed to
mprove the efﬁcacy of this powerful therapeutic tool,
ecause early MRD detection is a prerequisite to drive
ppropriate clinical maneuvers such as donor lympho-
yte infusions or the withdrawal of immune-suppres-
ive drugs. In fact, many hematologic malignancies
hat require allogeneic HSCT for treatment lack a
umor-speciﬁc molecular marker. In our series, 89%
f patients did not have such a marker and, thus, could
ot be monitored for disease relapse by standard mo-
ecular methods. Recent reports have shown that de-
ection of increased transcript levels of the Wilms
umor 1 gene (WT1) by real-time reverse transcrip-
ase-PCR can be a promising novel approach of uni-
ersal monitoring of disease recurrence in myeloid
eukemias, which in 50% of patients lack an alter-
ative tumor marker [30]. It is interesting to note that
lthough increased transcript levels of WT1 have been
hown to have a good correlation with relapse in
atients at diagnosis and after chemotherapy [31], R
00heir predictive value for disease recurrence after al-
ogeneic HSCT is subject to debate [32].
The classical approach to monitor the state of HC
fter allogeneic HSCT relies on the detection of short
andem repeats, which differ in length between patient
nd donor and can be characterized by capillary gel
lectrophoresis after ampliﬁcation by PCR [33]. In
ddition, in transplantation from female donors into
ale recipients, host cells can be traced by using
ytogenetics or ﬂuorescent in situ hybridization for
ale-speciﬁc genes on the Y chromosome [33]. The
dvantage of using mHags as markers for determina-
ion of the status of HC relies on the fact that this
ethod is cheap and easy to perform without the
equirement for sophisticated instrumentation, inde-
endently from donor and recipient sex. In addition,
hen nested PCR is used, mHags can be detected
ith an approximately 3-log higher sensitivity [20] as
ompared with short tandem repeats and ﬂuorescent
n situ hybridization, which have a detection threshold
f approximately 1% to 5% [33]. The biallelic nature
f HA-1 and HA-2 polymorphism renders these
arkers also suitable for quantitative analysis by real-
ime PCR. On the basis of these considerations, the
se of mHags for analysis of the HC status after
ransplantation may allow for a cheaper and more
imely diagnosis of mixed chimerism as compared
ith classical markers. As a consequence, their diag-
ostic application for follow-up of allogeneic HSCT
ay permit an early and therefore more efﬁcient ad-
quate clinical intervention, thereby ultimately im-
roving the therapeutic efﬁcacy of transplantation.
Taken together, the observations from this study
uggest that genomic typing for HA-1 and HA-2,
hich has a low cost and is easy to perform by most
aboratories involved in tissue typing for allogeneic
SCT, can be a powerful therapeutic and diagnostic
ool for an appreciable number of patients undergoing
llogeneic HSCT from a fully HLA-matched family
r unrelated donor. We propose that this analysis
hould be included in tests used for donor selection,
specially for patients with hematologic malignancies
ho lack a tumor-speciﬁc molecular marker.
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